RecruitingPhase 3Phase 4ACTRN12614000765628

Efficacy and safety of artemether-lumefantrine (AL) combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in 4 sites in India Annuppur district, Madhya Pradesh, Jhabua district, Madhya Pradesh, Bastar district, Chhattisgarh and Palamudistrict, Jharkhand

A study evaluating the efficacy and safety of artemether lumefantrine for the treatment of uncomplicated plasmodium falciparum infections in 4 sites in India Annuppur district, Madhya Pradesh, Jhabua district, Madhya Pradesh, Bastar district, Chhattisgarh and Palamudistrict, Jharkhand


Sponsor

Indian Council of Medical Research, Ministry of Health & Family welfare

Enrollment

352 participants

Start Date

Jun 10, 2014

Study Type

Interventional

Conditions

Summary

To study the efficacy of antimalarial drugs in India


Eligibility

Sex: Both males and femalesMin Age: 6 MonthssMax Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests how well a malaria treatment called artemether-lumefantrine (AL) works for people with uncomplicated Plasmodium falciparum malaria in certain regions of India. Researchers want to make sure this medicine is still effective against this type of malaria. You may be eligible if: - You are between 6 months and 60 years old - You have been diagnosed with P. falciparum malaria confirmed by blood test (not mixed with other malaria types) - You have a fever or history of fever in the last 24 hours - You are able to swallow oral medication - You are willing to follow the study schedule You may NOT be eligible if: - You have signs of severe or complicated malaria - You have a mixed malaria infection with another species - You are severely malnourished - You have another serious illness that could explain your fever - You are taking medications that affect how antimalarial drugs work - You are pregnant or breastfeeding - You are a sexually active woman of childbearing age unwilling to use contraception Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Artemether-lumefantrine will be administered according to body weight, twice a day over 3 days, as per WHO recommended dose (WHO guidelines). Tablets containing 20mg base of artemether and 120 mg base

Artemether-lumefantrine will be administered according to body weight, twice a day over 3 days, as per WHO recommended dose (WHO guidelines). Tablets containing 20mg base of artemether and 120 mg base of lumefantrine will be administered orally. The number of tablets administered is based on the weight of the patient, twice a day, over three days – 1 tablet for patients of 5-14kg, 2 for patients of 15-24kg, 3 for patients of 25-34kg, 4 over 34kg. All antimalarial drug(s) must be stored in a cool dry environment. All doses of medicine will be administered under the supervision of a qualified member of the staff designated by the principal investigator. The study patients will be observed for 30 min after medicine administration for adverse reactions or vomiting. Any patient who vomits during this observation period will be re-treated with the same dose of medicine and observed for an additional 30 min. If the patient vomits again, he or she will be withdrawn and offered rescue therapy. The therapeutic efficacy study will be carried out in the field clinic and 3-day treatment will be given at field clinic or their home by visiting each day for 3 days as in most malarious places public transport system is not available. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy


Locations(4)

Annuppur district, Madhya Pradesh, India

Jhabua district, Madhya Pradesh, India

Bastar district, Chhattisgarh, India

Palamudistrict, Jharkhand, India

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000765628


Related Trials